[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100092968":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":36,"collaborators":38,"id":45,"slug":7,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"University of Chicago","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Mary E Strek, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":7},"Vanita Patel, MPH","CONTACT","773-702-1012",[18],{"facility":5,"status":19,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"RECRUITING","Chicago","Illinois","60637","United States","US",{"type":26,"coordinates":27},"Point",[28,29],-87.65005,41.85003,{"lat":29,"lon":28},[32,35],{"name":10,"role":15,"phone":33,"phoneExt":7,"email":34},"773-702-3609","mstrek@medicine.bsd.uchicago.edu",{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[39,42],{"name":40,"class":41},"Idiopathic Pulmonary Fibrosis Clinical Research Network","NETWORK",{"name":43,"class":44},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH","100092968",false,"NCT00470327","A Study of the Natural Progression of Interstitial Lung Disease (ILD)","Inclusion Criteria:\n\n* Interstitial lung disease\n\nExclusion Criteria:\n\n* Does not have Interstitial lung disease",true,"ALL","18 Years",{"count":54,"type":55},4000,"ESTIMATED","OBSERVATIONAL","We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the \"phenotypic\" expression of these diseases.",[59,60,61,62],"Interstitial Lung Diseases","Idiopathic Pulmonary Fibrosis","Sarcoidosis","Connective Tissue Disorder",[64,65,61,66],"Interstitial lung diseases","idiopathic pulmonary fibrosis","mRNA and cytokine expression","2026-06-05",{"date":69,"type":70},"2026-06-09","ACTUAL",{"date":72,"type":70},"2005-09",{"date":74,"type":55},"2030-12",{"name":5,"class":6},1]